Zum Inhalt springen
skan clinical research

Clinical development and manufacturing

Designing scalable and compliant processes from Phase I onward

Mehr erfahren

The development of a finished pharmaceutical product requires strategic decisions early in its lifecycle. Already in early Phases, developers must define strategies that will impact the future manufacturing and eventually commercialization.

In Phase I or II, the primary container in which the product will ultimately be commercialized shall already be defined. This decision directly influences the future manufacturing strategy. Choosing the right filling concept and aseptic approach early helps avoid costly redesigns during late clinical phases or commercial scale-up.

Clinical development is characterized by uncertainty and evolution. Formulation may change, batch sizes are limited, and processes are frequently adapted. At the same time, regulatory expectations regarding sterility assurance and documentation apply from the earliest clinical batches.

Early-phase manufacturing often begins in flexible laboratory settings. As development progresses, operations move into more controlled environments such as RABS or isolators providing Grade A conditions. Without a clear long-term strategy, this transition can require fundamental process changes.

Designing clinical processes with commercial readiness in mind reduces technical risk, protects long-term investment and accelerates time to market.

At a glance

Key challenges in clinical development and manufacturing

  • Process flexibility

    Manufacturing platforms must adapt to changing processes, batch sizes, and product requirements as development progresses.

  • Outsourcing expertise

    Selecting a CDMO without fully understanding a product’s manufacturing needs can result in suboptimal technology choices, increased risk, and development setbacks.

  • Scalability and tech transfer

    Processes developed for clinical trials may not translate efficiently to commercial-scale manufacturing, leading to delays, added costs, and regulatory hurdles.

  • Speed to clinic

    Development timelines are often aggressive, requiring rapid process development without compromising quality.

  • Regulatory complexity

    Requirements can evolve throughout development, creating uncertainty and additional compliance efforts.

  • Supply chain reliability

    Delays or shortages of critical materials can impact manufacturing schedules and clinical timelines.

  • Personalized and advanced therapies

    Cell and gene therapies often require small, patient-specific batches and specialized manufacturing approaches that differ from traditional biologics.

Process

Typical clinical development evolution

  • 1

    Preclinical and laboratory phase

    Manual filling under bench-top or biosafety cabinet (BSC) conditions. The focus is on feasibility, formulation stability, and initial process definition.

  • 2

    Phase I-II production

    Small GMP batches are produced for clinical trials. Documentation requirements increase, and aseptic controls become more structured. RABS or isolator systems may be introduced to provide enhanced contamination control and production efficiency.

  • 3

    Preparation for commercialization

    As the product advances, regulatory requirements increase, batches grow in size and frequency, and usually more automation and containment is a must to ensure production robustness.

  • 4

    Commercialization

    Ensuring fit for purpose at each stage and continuity across these stages is essential. A filling concept that can transition from manual clinical batches to automated commercial production minimizes redevelopment and validation efforts.

Addressing the challenges

Tailored solutions for clinical workflows

Clinical development requires solutions that combine flexibility with long-term scalability.

  • Early integration of closed processing

    Closed filling concepts can be implemented even in small-batch or R&D environments, easily, rapidly and for a limited investment. This reduces contamination risks while maintaining operational simplicity.

  • Scalable filling technologies

    A consistent core technology can be applied from early clinical studies through commercial manufacturing. This enables both scale-up (higher batch volumes) and scale-out (parallel systems) without changing the fundamental process design. The availability of a size range of the same container, to accommodate different volumes and concentration imposed by product developments or to accommodate a complete product platform, should also be considered.

Addressing the challenges

Special technical requirements

  • Flexible containment concepts

    Manufacturing environments can evolve from BSC-based operations to RABS and fully integrated isolator systems providing Grade A conditions. This adaptability supports increasing regulatory and operational requirements.

  • Engineering and regulatory expertise

    Clinical manufacturers benefit from structured guidance on equipment selection, isolator integration, validation strategy, and GMP alignment. Early regulatory considerations help ensure smooth progression into later development phases.

    → Read more about the impact of Annex 1 on isolator design

An operator works in the PSI-L through the glove ports.

Expertise for clinical development and manufacturing

Clinical development sets the foundation for commercial success. Early decisions regarding container systems, aseptic concepts, and process scalability are critical.

SKAN supports biotech companies and pharmaceutical innovators in establishing reliable clinical manufacturing strategies and building flexible, compliant processes that remain scalable from first-in-human studies to market supply.

Our experience includes:

  • Transition from manual laboratory filling to controlled Grade A systems
  • Implementation of scalable aseptic filling concepts
  • Engineering and regulatory support during clinical progression

By combining process expertise, containment solutions, and regulatory understanding, we help manufacturers move confidently from early trials to commercialization.

Let’s talk about your clinical manufacturing strategy

Let’s explore how to design a clinical manufacturing pathway that remains flexible today and scalable tomorrow.

Nehmen Sie Kontakt auf!

Ob Sie eine Frage zu unseren Produkten haben, technische Unterstützung benötigen oder mehr über unsere Lösungen erfahren möchten – wir sind für Sie da.

Zurück nach oben